GLP-1 and Blindness
Update: 2025-06-10
Description
<figure class="wp-caption alignright" id="attachment_10144" style="width: 255px;">
<figcaption class="wp-caption-text" id="caption-attachment-10144">photo of intermediate macular degeneration c National Institutes of Health</figcaption></figure>
<figcaption class="wp-caption-text" id="caption-attachment-10144">photo of intermediate macular degeneration c National Institutes of Health</figcaption></figure>We talk with scientists who report that a common weight loss/diabetes drug known as a GLP-1 receptor agonist (Wegovy, Ozempic for instance) is associated with an increased risk of blindness. The study was published last week in the Journal of the American Medical Association Ophthalmology, about a form of blindness known as “wet” macular degeneration. The scientists we talk with today are Marko Popovic and Reut Shor. We also refer to a different, unrelated study, underway, to evaluate a ketogenic diet and eye health, specifically, whether or not a ketogenic diet can reduce diabetes while providing better protection to the eye.
Executive Producer: Joel Parker
Show Producer: Shelley Schlender
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
